StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
Regeneron Pharmaceut
971.19
-1.18%
 

REGN

 

Regeneron Pharmaceuticals

$ 971.19

 
-$11.63 | -1.18%
 
 
Open
$ 982.82
 
 
MKT CAP
$ 106.60B
 
High
$ 985.21
 
 
VOL
$ 406.19K
 
Low
$ 966.22
 
 
AVG VOL
$ 0.50M
 
 
 

REGN Stock Analysis

  Login to display Regeneron Pharmaceuticals (REGN) recommendation from the last 90 days from financial news and social media.
 
 

REGN Total Score

 
 

Strengths

REGN Rewards

 Earnings are forecast to grow

REGN Rewards

 Analysts raised price target

REGN Rewards

 Outperform the market

REGN Rewards

 Investors confidence is positive

 

Risk Analysis

REGN Risk Analysis

 Insider selling during the past 3 months

 
 

Chart

 
 

942.83

835.75

808.47

743.75

 
 
1month
3month
6month
1year
 
Total Return
REGN
vs.
S&P500
 

 
1-week Return
-2.23%
 
+1.04%
 
 
5-week Return
+3.31%
 
+4.91%
 
 
10-week Return
+14.47%
 
+7.60%
 
 
 

REGN Risk Level

This Indicator assigning REGN risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
REGN Risk Level
LOW
HIGH

Risk Volatility

 

REGN has Low Risk Level

Click here to check what is your level of risk

 

REGN Analysts Opinion

REGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

3.00
 

REGN Earnings Sentiment

 Above analyst estimates

REGN Earnings Sentiment

 Sales decline

 
 

Rating

×
 

Rating

3.00
 
 

Momentum

×
 

Momentum

3.33
 

REGN Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

3.45
 

REGN Activity Sentiment

 Insider selling during the past 3 months

REGN Activity Sentiment

 Investors confidence is positive

 

Future

×
 

Future

3.23
 

REGN Future Sentiment

 Earnings are forecast to grow

REGN Future Sentiment

 Analysts raised price target

REGN Future Sentiment

 Outperform the market

 
 

REGN Analysts Opinion

REGN Analysts opinion is positive but there was a setback from the past 3 months

 

REGN Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
62%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
67%
62%
 
On Track
On Track
On Track
 

REGN Street Opinion 

REGN Street view is bullish and have positive views on the near-term outlook

 

REGN Performance Sentiment

Sentiments overview associated with REGN events and the stock performance.
 
62%
30%
Positive
Negative
23 out of 37
events present
11 out of 37
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

REGN Earnings

The TTM reflects 12-month period, providing review of REGN financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
13,117
13,117
12,173
+3.81%
 
 
Cost of Revenue
1,816
1,816
1,560
+7.89%
 
 
Gross Profit
11,301
11,301
10,613
+3.19%
 
 
Operating Exp
7,068
7,068
5,619
+12.16%
 
 
Operating Inc
4,233
4,233
4,994
-7.93%
 
 
Net Interest Inc
423
423
101
+104.65%
 
 
Interest Exp
73
73
59
+11.23%
 
 
Interest Inc
496
496
160
+76.07%
 
 
Other Income
-457
-457
-236
-
 
 
EPS
37.37
-
40.51
-3.95%
 
 
Next Earnings Date: May 02, 2024
 
 
Similar to REGN
Total Score
Close Price
%
Change

CELU

Celularity Clas

N/A

4.26

+16.39%

 

XERS

Xeris Pharma

N/A

3.04

-4.40%

 

TSVT

2seventy bio Inc.

N/A

5.42

-3.90%

 

SNY

Sanofi

3.31

47.15

-0.30%

 
 
 
Highlights
Last Modify
Price
% Change

 
Price Target Reached
This Week
987.61
-0.58%
 
Insider Selling
1 Week Ago
964.89
+1.26%
 
Approvals
1 Week Ago
952.84
+0.63%
 
Price Target Raised
3 Weeks Ago
937.81
+0.16%
 
Strong Earnings
2 Month Ago
945.18
-1.32%
 
 
 
joker
 
 
 
StocksRunner

Explore our REGN Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our REGN Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

REGN Rewards

 Earnings are forecast to grow

REGN Rewards

 Analysts raised price target

REGN Rewards

 Outperform the market

REGN Rewards

 Investors confidence is positive

 

Risk Analysis

 

REGN Risk Analysis

 Insider selling during the past 3 months

 
 
 

REGN Risk Level

 
 
 

The Indicator assigning REGN risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
REGN Risk Level
LOW
HIGH

Risk Volatility

 

REGN has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

REGN

 

Regeneron Pharmaceuticals

$ 971.19

 
-$11.63 | -1.18%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 982.82
 
 
MKT CAP
$ 106.60B
 
High
$ 985.21
 
 
VOL
$ 406.19K
 
Low
$ 966.22
 
 
AVG VOL
$ 0.50M
 
 
 

REGN Analysis

  Sign in to view Regeneron Pharmaceuticals (REGN) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

942.83

835.75

808.47

743.75

 
 
1month
3month
6month
1year
 
Total Return
REGN
vs.
S&P500
 

 
1-week Return
-2.23%
 
+1.04%
 
 
5-week Return
+3.31%
 
+4.91%
 
 
10-week Return
+14.47%
 
+7.60%
 
 
 

REGN Analysts Opinion

REGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

3.00
 

REGN Earnings Sentiment

 Above analyst estimates

REGN Earnings Sentiment

 Sales decline

 
 

Rating

×
 

Rating

3.00
 
 

Momentum

×
 

Momentum

3.33
 

REGN Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

3.45
 

REGN Activity Sentiment

 Insider selling during the past 3 months

REGN Activity Sentiment

 Investors confidence is positive

 

Future

×
 

Future

3.23
 

REGN Future Sentiment

 Earnings are forecast to grow

REGN Future Sentiment

 Analysts raised price target

REGN Future Sentiment

 Outperform the market

 
 

REGN Analysts Opinion

REGN Analysts opinion is positive but there was a setback from the past 3 months

 

REGN Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
62%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
67%
62%
 
On Track
On Track
On Track
 

REGN Street Opinion 

REGN Street view is bullish and have positive views on the near-term outlook

 
REGN Performance Sentiment
Sentiments overview associated with REGN events and the stock performance.
 
62%
30%
Positive
Negative
23 out of 37
events present
11 out of 37
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

REGN Earnings

The TTM data reflects the most recent 12-month period, providing overview of REGN financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
13,117
13,117
12,173
+3.81%
 
 
Cost of Revenue
1,816
1,816
1,560
+7.89%
 
 
Gross Profit
11,301
11,301
10,613
+3.19%
 
 
Operating Exp
7,068
7,068
5,619
+12.16%
 
 
Operating Inc
4,233
4,233
4,994
-7.93%
 
 
Net Interest Inc
423
423
101
+104.65%
 
 
Interest Exp
73
73
59
+11.23%
 
 
Interest Inc
496
496
160
+76.07%
 
 
Other Income
-457
-457
-236
-
 
 
EPS
37.37
-
40.51
-3.95%
 
 
Next Earnings Date: May 02, 2024
 
Highlights
Last Modify
Price
% Change

 
Price Target Reached
This Week
987.61
-0.58%
 
Insider Selling
1 Week Ago
964.89
+1.26%
 
Approvals
1 Week Ago
952.84
+0.63%
 
Price Target Raised
3 Weeks Ago
937.81
+0.16%
 
Strong Earnings
2 Month Ago
945.18
-1.32%
 
 
REGN Latest News Feed

Regeneron Pharmaceuticals Reaches Analyst Target Price. In recent trading shares of Regeneron Pharmaceuticals Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $993.21 changing hands for $993.35/share. When a s

Wed Feb 28, 2024

Potential

The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts. Across the recent three months 10 analysts have shared their insights on Regeneron Pharmaceuticals (NASDAQ:) expressing a variety of opinions spanning from ish to bearish. The foll

Tue Feb 27, 2024

Potential

(REGN) - Analyzing Regeneron Pharmaceuticalss Short Interest. ) short percent of float has risen 15.38% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet be

Thu Feb 22, 2024

Activity
Momentum

Regeneron multiple myeloma therapy granted FDA priority review.

Wed Feb 21, 2024

Activity

Starbucks Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling. The Nasdaq 100 closed lower by over 150 points on Friday. Investors meanwhile focused on some notable insider trades. When insiders sell shares it could be a preplanned sale or

Tue Feb 20, 2024

Activity

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2023.

Sat Feb 10, 2024

Activity

stakes are high for regenerons eylea hd as genentechs vabysmo continues to gain momentum prompting doctors to weigh their options between two industry titans according to spherix global insights.

Thu Feb 8, 2024

Momentum

stakes are high for regenerons eylea hd as genentechs vabysmo continues to gain momentum prompting doctors to weigh their options between two industry. exton pennsylvania feb. 08 2024 (globe newswire) -- as age-related macular degeneration (amd) awareness

Thu Feb 8, 2024

Momentum

cantor fitzgerald maintains neutral rating for regeneron pharmaceuticals: heres what you need to know. cantor fitzgerald has decided to maintain its neutral rating of regeneron pharmaceuticals (nasdaq:) and raise its price target from $850.00 to $925.00.

Tue Feb 6, 2024

Momentum
Potential
Rating

regeneron (regn) q4 earnings & sales top eylea sales decline. regeneron pharmaceuticals inc. regn delivered better-than-expected fourth-quarter 2023 results despite declining sales of its lead

Fri Feb 2, 2024

Earnings
Earnings

regeneron earnings beat forecasts as sales of updated eye drug raise hopes.

Fri Feb 2, 2024

Earnings

regeneron posts q4 beat even as eylea covid-19 sales dip.

Fri Feb 2, 2024

Earnings

regeneron pharmaceuticals beats top-line and bottom-line estimates. initiates fy24 outlook.

Fri Feb 2, 2024

Earnings

regeneron announces formation of regeneron cell medicines with acquisition of 2seventy bio. (rttnews) - regeneron pharmaceuticals inc. (regn) announced the formation of regeneron cell medicines based on an agreement with 2seventy bio to acquire

Tue Jan 30, 2024

Activity

2seventy stock rises as regeneron acquires r&d assets.

Tue Jan 30, 2024

Momentum

breaking down regeneron pharmaceuticals: 14 analysts share their views. during the last three months 14 analysts shared their evaluations of regeneron pharmaceuticals (nasdaq:) revealing diverse outlooks from ish to bearish. the following table summarize

Mon Jan 29, 2024

Potential

benjamin graham detailed fundamental analysis - regn. below is valideas guru fundamental report for regeneron pharmaceuticals inc (regn). of the 22 guru strategies we follow regn rates highest using our value investor model based on the publish

Fri Jan 26, 2024

Potential

regeneron receives fda approval for dupixent for patients aged 1 to 11 years. (rttnews) - regeneron pharmaceuticals inc. (regn) and sanofi on thursday announced that the fda has approved dupixent (dupilumab) for treating pediatric patients aged

Thu Jan 25, 2024

Activity

regn crosses above average analyst target. in recent trading shares of regeneron pharmaceuticals inc. (symbol: regn) have crossed above the average analyst 12-month target price of $954.00 changing hands for $954.58/share. when a stock reaches

Wed Jan 24, 2024

Potential
Potential

this is what whales are betting on regeneron pharmaceuticals. investors with a lot of money to spend have taken a ish stance on ). and retail traders should know. we noticed this today when the trades showed up on publicly available options history that

Fri Jan 19, 2024

Activity

benjamin graham detailed fundamental analysis - regn. below is valideas guru fundamental report for regeneron pharmaceuticals inc (regn). of the 22 guru strategies we follow regn rates highest using our value investor model based on the publish

Fri Jan 19, 2024

Potential

regeneron and petco health and wellness have been highlighted as zacks and bear of the day. for immediate releasechicago il &ndash. january 17 2024 &ndash. zacks equity research shares regener

Wed Jan 17, 2024

Momentum

rbc ups regeneron to outperform. cites eylea patent win dupi sales.

Fri Jan 12, 2024

Activity
Potential

regeneron eyes wegovy combo to improve quality of weight loss.

Wed Jan 10, 2024

Potential

regeneron (regn) down as q4 eylea preliminary sales disappoint. shares of regeneron pharmaceuticals inc. regn declined 1.13% after the company reported disappointing fourth-quarter preliminary

Tue Jan 9, 2024

Activity
Activity

beyond the numbers: 13 analysts discuss regeneron pharmaceuticals stock. during the last three months 13 analysts shared their evaluations of regeneron pharmaceuticals (nasdaq:) revealing diverse outlooks from ish to bearish. the table below summarizes t

Tue Jan 9, 2024

Potential

benjamin graham detailed fundamental analysis - regn. below is valideas guru fundamental report for regeneron pharmaceuticals inc (regn). of the 22 guru strategies we follow regn rates highest using our value investor model based on the publish

Mon Jan 8, 2024

Potential

regeneron preliminary q4 us sales of eylea below expectations. regeneron pharmaceuticals on monday reported eye drug eyleas fourth-quarter preliminary United States sales below wall street expectations as the companys blockbuster product faced p

Mon Jan 8, 2024

Earnings

guru fundamental report for regn - benjamin graham. below is valideas guru fundamental report for regeneron pharmaceuticals inc (regn). of the 22 guru strategies we follow regn rates highest using our value investor model based on the published

Thu Jan 4, 2024

Potential

 
 
 
 
 

Score Tracker

 
 
 
Based on 37 events in the last 90 days from financial news and social media. Last updated Mar 4, 2024 19:26 Wall St. time
 
 

REGN Total Score

 
 
 
 
 
 
 
StocksRunner

Discover REGN Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of REGN. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our REGN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

REGN Stock trends

REGN Stock performance

REGN Stock analysis

REGN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker